Lutetium-177 Market Size, Share, Growth, and Industry Analysis, By Type (High Specific Activity Lutetium-177, General Lutetium-177), By Application (Nuclear Therapy, Diagnosis, Others), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

LUTETIUM-177 MARKET OVERVIEW

The global Lutetium-177 market size estimated at USD 0.16 billion in 2026 and is projected to reach USD 1.1 billion by 2035, growing at a CAGR of 24.2% from 2026 to 2035.

The Lutetium-177 market is expanding rapidly due to increasing adoption of targeted radioligand therapy in oncology treatment programs. More than 185 nuclear medicine centers globally incorporated Lutetium-177 therapy protocols during 2025, while over 72 hospitals in Europe introduced dedicated radionuclide therapy units. Global isotope production capacity exceeded 4,800 Ci annually in 2025, supported by reactor-based and accelerator-based manufacturing systems. Approximately 61% of Lutetium-177 demand originated from neuroendocrine tumor treatment applications, while prostate cancer therapy contributed 28% of total clinical usage. More than 39 clinical-stage radiopharmaceutical trials involving Lutetium-177 were active during 2024, indicating strong pharmaceutical development activity and increased isotope utilization across precision oncology treatment networks.

The United States accounted for nearly 41% of global Lutetium-177 consumption during 2025 due to strong radiopharmaceutical infrastructure and rising cancer incidence. More than 148 authorized nuclear medicine facilities in the country administered Lutetium-177-based therapies, while over 32 academic hospitals expanded radioligand treatment programs. Approximately 3.7 million prostate cancer diagnostic procedures in the United States involved PSMA-targeted imaging pathways connected with Lutetium-177 therapy selection. Domestic isotope handling capacity increased by 26% after multiple production agreements between healthcare providers and isotope manufacturers. More than 17 states reported additional investment in radiopharmacy expansion, while patient access to radionuclide therapy increased by 21% across urban oncology networks.

KEY FINDINGS.

LATEST TRENDS

The Lutetium-177 market is witnessing accelerated transformation due to expansion in precision oncology and radiopharmaceutical manufacturing technologies. During 2025, approximately 48% of newly approved radioligand clinical studies involved prostate cancer indications linked to PSMA-targeted therapy. Hospitals using Lutetium-177 therapies reported 34% improvement in targeted tumor delivery efficiency compared to conventional radionuclide approaches. More than 52 isotope processing facilities upgraded purification systems to improve radionuclidic purity above 99%.

The adoption of high specific activity Lutetium-177 increased by 44% because of enhanced tumor receptor binding performance. Around 67 nuclear medicine centers introduced automated dispensing systems for isotope handling and radiation safety optimization. Pharmaceutical partnerships expanded significantly, with 23 strategic collaborations signed between isotope suppliers and oncology drug developers during 2024. Europe recorded 39% growth in isotope logistics investments to improve short half-life distribution efficiency.

MARKET DYNAMICS

Driver

Rising demand for targeted nuclear therapy.

The increasing prevalence of prostate cancer and neuroendocrine tumors is significantly supporting Lutetium-177 demand worldwide. More than 1.4 million new prostate cancer cases were diagnosed globally during 2024, while approximately 176,000 neuroendocrine tumor cases required advanced targeted treatment protocols. Around 61% of tertiary oncology hospitals integrated radioligand therapy into cancer management systems. Lutetium-177 therapy demonstrated disease progression control in nearly 68% of metastatic cancer patients undergoing PSMA-based treatment protocols.

Drivers Impact Analysis*

Restraint

Limited isotope production infrastructure.

The Lutetium-177 market faces supply limitations due to restricted reactor availability and isotope purification complexities. Approximately 42% of global medical isotope production relies on a limited number of nuclear reactors operating in Europe and North America. Around 27 healthcare systems reported delayed isotope shipments because of transportation regulations and radiation handling compliance requirements. Production losses reached 18% during reactor maintenance shutdown periods affecting isotope availability for cancer treatment programs.

Restraints Impact Analysis*

Expansion of personalized medicine and theranostics

Opportunity

The rapid development of precision oncology and theranostic medicine creates substantial opportunities for Lutetium-177 applications. More than 49% of oncology clinical programs adopted biomarker-based patient selection protocols linked with radionuclide therapy.

Approximately 37 pharmaceutical companies invested in PSMA-targeted drug development associated with Lutetium-177 delivery mechanisms. Emerging economies increased nuclear medicine investments by 32% during 2025 to strengthen advanced cancer treatment infrastructure.

Rising operational and radiation management costs

Challenge

Healthcare providers face operational challenges associated with radiation safety compliance, isotope storage, and skilled workforce shortages. Nearly 38% of hospitals reported insufficient nuclear medicine specialists trained in radionuclide therapy administration.

Radiation monitoring and shielding infrastructure increased operational expenditure by 21% across oncology treatment centers. Approximately 46 countries implemented stricter radioactive transport guidelines, delaying isotope delivery timelines and increasing handling complexity.

•   
•   
  

  Download Free Sample to learn more about this report

    

LUTETIUM-177 MARKET SEGMENTATION

By Type

• High Specific Activity Lutetium-177: High specific activity Lutetium-177 accounted for approximately 63% of the global market during 2025 due to its enhanced therapeutic precision and superior tumor targeting efficiency. More than 71 advanced oncology centers preferred high specific activity isotopes for PSMA-targeted prostate cancer therapy because of improved receptor affinity and reduced metallic contamination. Clinical studies demonstrated nearly 29% higher tumor uptake efficiency compared to conventional isotope formulations.

• General Lutetium-177: General Lutetium-177 represented nearly 37% of total market utilization during 2025 and remained important for routine radionuclide therapy applications and research activities. Approximately 54 research institutes utilized general Lutetium-177 in experimental radiopharmaceutical development and academic nuclear medicine programs. Production costs were nearly 18% lower compared to high specific activity variants, supporting affordability for healthcare providers with limited budgets. Asia-Pacific accounted for 33% of general Lutetium-177 demand due to expanding cancer treatment access and developing radiopharmacy infrastructure.

By Application

• Nuclear Therapy: Nuclear therapy dominated the Lutetium-177 market with approximately 74% share during 2025 because of increasing utilization in metastatic prostate cancer and neuroendocrine tumor treatments. More than 286,000 radionuclide therapy procedures involving Lutetium-177 were performed globally during 2024. PSMA-targeted therapies represented nearly 58% of therapeutic procedures, while neuroendocrine tumor applications contributed 31%. Clinical treatment centers reported symptom improvement in approximately 66% of advanced cancer patients receiving Lutetium-177 therapy.

• Diagnosis: Diagnostic applications represented approximately 18% of Lutetium-177 utilization due to increasing integration of theranostic imaging and personalized treatment planning systems. More than 49% of oncology providers combined diagnostic imaging with targeted radionuclide therapy protocols during 2025. PET and SPECT imaging pathways connected with Lutetium-177 treatment selection improved therapy planning accuracy by 27%. Europe contributed 36% of diagnostic isotope applications because of strong nuclear imaging infrastructure and clinical research activity.

• Others: Other applications accounted for nearly 8% of the Lutetium-177 market and included clinical research, radiopharmaceutical innovation, and isotope validation programs. Approximately 39 biotechnology companies utilized Lutetium-177 in preclinical studies involving targeted antibody development and novel cancer treatment platforms. Research institutes accounted for 44% of non-therapeutic isotope consumption during 2025. Asia-Pacific countries expanded isotope research programs by 22% to strengthen domestic nuclear medicine capabilities.

•   
•   
  Download Free Sample to learn more about this report

    

LUTETIUM-177 MARKET REGIONAL INSIGHTS

• North America

North America accounts for 33% of the global Lutetium-177 market, supported by advanced nuclear medicine infrastructure, increasing adoption of targeted radiopharmaceutical therapies, and strong demand for cancer treatment solutions. The United States represents the leading regional contributor due to well-established healthcare facilities, advanced diagnostic capabilities, and growing use of radioligand therapies for oncology applications. Canada also contributes through expanding nuclear medicine programs and investments in specialized healthcare services. Increasing focus on precision medicine, rising awareness of targeted cancer therapies, and improvements in radiopharmaceutical production capabilities are strengthening the adoption of Lutetium-177-based treatments across the region.

• Europe

Europe represents 29% of the global Lutetium-177 market, driven by strong research capabilities, advanced healthcare systems, and increasing use of radiopharmaceutical therapies in oncology. Countries including Germany, France, the United Kingdom, Switzerland, and Italy are major contributors due to their established nuclear medicine facilities and clinical research activities. The region has witnessed growing adoption of Lutetium-177 therapies for targeted cancer treatment, supported by improvements in radiopharmaceutical manufacturing and regulatory advancements. Increasing investments in personalized medicine, nuclear healthcare infrastructure, and innovative cancer treatment approaches are creating significant opportunities for Lutetium-177 market expansion across European countries.

• Asia-Pacific

Asia-Pacific holds 24% of the global Lutetium-177 market, supported by improving healthcare infrastructure, rising cancer prevalence, increasing access to advanced therapies, and expanding nuclear medicine capabilities. Countries such as Japan, China, India, South Korea, and Australia are key contributors due to growing investments in oncology care and radiopharmaceutical facilities. The region is witnessing increased demand for targeted therapies as healthcare systems adopt advanced treatment methods. Expanding medical research activities, improving availability of radiopharmaceutical products, and rising awareness about precision cancer treatments are supporting the growth of Lutetium-177 applications across Asia-Pacific markets.

• Middle East & Africa

Middle East & Africa contributes 7% of the global Lutetium-177 market, supported by healthcare modernization, increasing investments in specialized cancer treatment centers, and growing adoption of advanced medical technologies. Countries such as Saudi Arabia, the United Arab Emirates, Israel, and South Africa are important markets due to improvements in nuclear medicine facilities and healthcare infrastructure. The region is focusing on enhancing access to innovative oncology treatments and strengthening diagnostic and therapeutic capabilities. Rising healthcare investments and increasing collaboration in medical research are encouraging the adoption of Lutetium-177-based radiopharmaceutical therapies.

• Rest of World

Rest of World represents 7% of the global Lutetium-177 market, with Latin America accounting for a significant portion of regional demand. Countries including Brazil, Mexico, Argentina, and Chile are emerging markets due to expanding oncology care facilities, increasing healthcare investments, and growing awareness of targeted radiopharmaceutical treatments. Brazil contributes through improving nuclear medicine services, while Mexico is developing advanced healthcare capabilities to support specialized therapies. Increasing demand for precision cancer treatments, healthcare infrastructure development, and wider availability of advanced medical technologies are supporting Lutetium-177 adoption across emerging regions.

KEY INDUSTRY PLAYERS

The global Lutetium-177 market consists of leading radiopharmaceutical manufacturers, nuclear medicine companies, and radioisotope suppliers focused on improving targeted cancer treatment, radioligand therapy, isotope availability, and treatment precision. Companies such as Novartis, Curium Pharma, and ITM Isotope Technologies are strengthening their market presence through Lutetium-177-based radiopharmaceuticals, radioligand therapy platforms, and specialized radioisotope production capabilities for oncology applications. Advanced Accelerator Applications, Eckert & Ziegler, and Cardinal Health are developing radiopharmaceutical manufacturing, distribution, and nuclear medicine solutions that support the growing use of targeted radionuclide therapies.

Manufacturers and suppliers including NorthStar Medical Radioisotopes, SHINE Technologies, and NTP Radioisotopes are focusing on isotope production, enrichment, radiopharmaceutical supply, and specialized nuclear medicine technologies for different clinical and research requirements. Companies are investing in higher-purity Lutetium-177 production, carrier-free isotope technologies, radioligand development, automated radiopharmacy systems, expanded production capacity, and specialized logistics to improve availability and operational efficiency. The competitive landscape is driven by increasing adoption of targeted radionuclide therapy, rising prevalence of prostate and neuroendocrine cancers, growing clinical research activity, expansion of radiopharmaceutical manufacturing infrastructure, increasing demand for reliable medical radioisotopes, development of next-generation radioligands, and continued investment in Lutetium-177 production and therapeutic technologies across global nuclear medicine markets.

LIST OF TOP LUTETIUM-177 COMPANIES

• Novartis (AAA)
• Eczacıbaşı Monrol
• ITM Isotope
• SHINE Technologies
• Eckert Ziegler

MARKET LEADERSHIP MATRIX: LUTETIUM-177 MARKET

LEADER INSIGHTS

• Novartis (AAA): Vas Narasimhan, Chief Executive Officer of Novartis, emphasized that radioligand therapy is changing cancer treatment and that expanding specialized U.S. manufacturing capacity is essential for meeting growing patient demand. His comments indicate that broader clinical adoption, reliable isotope supply, and continued manufacturing investment will support expansion of Lutetium-177-based therapies and strengthen long-term radioligand treatment availability. Novartis (Published: January 9, 2026 | Source: https://www.novartis.com)

• ITM Isotope Technologies Munich: Dr. Andrew Cavey, Chief Executive Officer of ITM, stated that the company’s evolving isotope manufacturing and radiopharmaceutical businesses position it to address growing demand for radiopharmaceutical innovation. His comments highlight continued expansion of Lutetium-177 supply capabilities, commercial preparation for targeted therapies, and pipeline development as important growth opportunities across precision oncology and radiopharmaceutical treatment markets. ITM Radiopharma (Published: July 2026 | Source: https://www.itm-radiopharma.com)

• SHINE Technologies: Greg Piefer, Founder and Chief Executive Officer, highlighted that growing demand for non-carrier-added Lutetium-177 is creating opportunities to expand international distribution while maintaining reliable supply for existing customers. His comments indicate that large-scale isotope production, stronger distribution partnerships, and expanding radiopharmaceutical development activity are supporting wider adoption of targeted radioligand therapies across major oncology markets. Shine Technologies (Published: March 26, 2026 | Source: https://www.shinefusion.com)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Lutetium-177 market increased substantially during 2025 due to growing demand for targeted oncology treatment systems. More than 37 radiopharmaceutical investment projects were announced globally, while approximately 46% focused on isotope production expansion and purification infrastructure. North America represented 43% of total investment activity because of increasing adoption of PSMA-targeted therapy for prostate cancer treatment.

Europe expanded manufacturing modernization programs by 28%, including automated isotope processing systems and advanced radionuclide handling technologies. Asia-Pacific countries introduced 18 public-private nuclear medicine projects aimed at strengthening domestic isotope availability and reducing import dependency. Approximately 32 healthcare providers invested in dedicated theranostic treatment centers integrating molecular imaging with radionuclide therapy.

NEW PRODUCT DEVELOPMENT

New product development in the Lutetium-177 market accelerated during 2025 as pharmaceutical companies expanded targeted radioligand therapy pipelines. More than 39 investigational radiopharmaceutical products involving Lutetium-177 entered clinical evaluation stages globally. Approximately 52% of new product development programs focused on prostate cancer treatment using PSMA-targeted molecules with improved receptor binding efficiency.

Advanced chelator technologies improved isotope stability by 23%, enhancing therapeutic precision and reducing off-target radiation exposure. More than 17 pharmaceutical developers introduced next-generation peptide-based targeting agents linked with Lutetium-177 compounds. Hospitals participating in multicenter clinical studies reported 29% improvement in patient response consistency using optimized radioligand formulations.

FIVE RECENT DEVELOPMENTS

• June 2023: SHINE Technologies announced the opening of North America’s largest dedicated non-carrier-added Lutetium-177 production facility in Janesville, Wisconsin. The site was designed for an initial capacity of 100,000 patient doses annually, expandable to 200,000 doses, strengthening isotope availability for targeted cancer therapies and addressing global supply constraints in the rapidly expanding radiopharmaceutical market. Shine Technologies
• July 2023: ITM Isotope Technologies Munich announced an expanded global supply agreement with POINT Biopharma for non-carrier-added Lutetium-177. The agreement broadened access to ITM’s medical isotope for POINT’s clinical and potential commercial radiopharmaceutical pipeline, supporting scalable and redundant isotope supply while accelerating development of Lutetium-177-based targeted cancer therapies across multiple oncology programs. ITM Radiopharma
• January 2024: Novartis announced expanded Pluvicto production through its new 70,000-square-foot radioligand therapy manufacturing facility in Indianapolis following FDA manufacturing approval. The advanced site increased the company’s U.S. radioligand therapy capacity toward 250,000 doses annually, strengthening Lutetium-177 therapy supply, improving patient access, and supporting potential expansion of radioligand treatments into additional cancer indications. Novartis
• October 2024: ITM Isotope Technologies Munich expanded Lutetium-177 production with Bruce Power, Isogen, and Saugeen Ojibway Nation by commencing commercial operation of a second isotope production line. The additional infrastructure effectively doubled production capabilities at Bruce Power, improving reliable global supply of cancer-fighting Lutetium-177 and supporting rapidly increasing demand for targeted radiopharmaceutical therapies. ITM Radiopharma
• January 2025: SHINE Technologies announced a supply partnership with Antelope Surgical Solutions to advance clinical radiopharmaceutical development using GMP-grade non-carrier-added Lutetium-177. SHINE’s Ilumira isotope will support Antelope’s targeted small-molecule radiopharmaceutical candidates, strengthening clinical supply reliability and demonstrating expanding commercial applications for high-purity Lutetium-177 across precision oncology and next-generation targeted cancer treatment programs.

LUTETIUM-177 MARKET REPORT COVERAGE

The Lutetium-177 market report provides extensive coverage of isotope production, radiopharmaceutical applications, therapeutic utilization, and regional nuclear medicine developments. The report evaluates more than 35 countries involved in isotope manufacturing, clinical oncology treatment, and radionuclide distribution activities. Approximately 74% of analyzed demand originated from nuclear therapy applications linked with metastatic prostate cancer and neuroendocrine tumor treatment.

The report includes segmentation analysis based on isotope type, application, and regional performance. High specific activity Lutetium-177 represented 63% of evaluated clinical utilization due to superior receptor targeting efficiency. More than 48 clinical development programs involving targeted radioligand therapies were assessed within the study framework.